Year Published
- (-) Remove 2008 filter 2008
- 2009 (0)
- 2010 (2) Apply 2010 filter
- 2011 (6) Apply 2011 filter
- 2012 (2) Apply 2012 filter
- 2013 (0)
- (-) Remove 2014 filter 2014
- 2015 (4) Apply 2015 filter
- 2016 (7) Apply 2016 filter
- 2017 (10) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (1) Apply Countries/Governments filter
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (1) Apply Research Brief filter
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (3) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (3) Apply Sub-Saharan Africa filter
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (1) Apply LSMS & LSMS-ISA filter
- Other Datasets (1) Apply Other Datasets filter
Current search
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- (-) Remove Aid & Other Development Finance filter Aid & Other Development Finance
- (-) Remove 2014 filter 2014
- (-) Remove 2008 filter 2008
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
In this brief, we report on measures of economic growth, poverty and agricultural activity in Ethiopia. For each category of measure, we first describe different measurement approaches and present available time series data on selected indicators. We then use data from the sources listed below to discuss associations within and between these categories between 1994 and 2017.
This report summarizes current trends in the application of Development Finance Institution (DFI)-based returnable capital finance in developing countries, with an emphasis on “pro-poor” development initiatives. We begin by reviewing the financial instruments used by DFIs. We then review the major DFI providers of returnable-capital based finance, drawing on past and present peer-reviewed articles and published reports exploring trends in the uses of different returnable capital instruments over time. Finally, we conclude by further examining recent efforts to use returnable capital to finance development initiatives explicitly targeting the poor.